Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 166OTHER 83NIH 9NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 52Cyclophosphamide 45Vincristine 37Cisplatin 31Radiotherapy 30Radiation 30Carboplatin 29Dexamethasone 28Etoposide 26Biopsy 26Doxorubicin 24daratumumab 18Prednisone 18Radiotherapy, Intensity-Modulated 17durvalumab 16Platinum 16Irinotecan 16Cytarabine 16Paclitaxel 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Methotrexate 14Leucovorin 14Docetaxel 14Observation 13Lenalidomide 13Radiotherapy, Conformal 12Fluorouracil 12Calcium Dobesilate 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Injections × 1 year × Clear all
NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Oncology Group

Phase 3 Recruiting
1,186 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡